PT88837B - METHOD FOR THE PREPARATION OF ACIDS AND AZETIDINYL-QUINOLON-CARBOXYLIC ACID ESTERS - Google Patents

Abstract

Quinoline derivs. of formula (I) and their pharmaceutically acceptable salts are new. - In (I), R1 = OH, 1-6C alkoxy or NR4R5; R4 and R5 = H or 1-6C alkyl; R2 = H, OH, 1-6C alkanoylamino, morpholine, halo, CN, 1-6C hydroxyalkyl, COOR6, 1-6C alkoxy or NR7R8; R6 = H or 1-6C alkyl; R7 and R8 = H, 1-6C alkyl, 2-6C aminoalkyl, 2-6C alkylamin-(2-6C)alkyl or di(1-6C alkyl)amino-(1-6C)alkyl; R3 = H, 1-6C alkyl or phenyl (opt. substd. by 1-2 of 1-6C alkyl, NO2, NH2, halo, 1-2C alkyl substd. by 1-5 halo, OH, or 1-6C alkoxy. Pref. R1 = NH2 or esp. OH; R2 = H, NH2, OH, acetylamino, CH2OH or COOR6 (esp. H, NH2 or OH); R6 = H; R3 = H or phenyl; and salt = alkali(ne earth) metal salt. - 6 Cpds. (I) viz. 1-cyclopropyl- 6-fluoro-1,4-dihydro-7-Q-4-oxo-3- quinolinecarboxylic acid (Q = 1-azetidinyl, 3-hydroxy-1-azetidinylm 3-amino-1-azetidinyl, 3-acetyl amino-1-azetidinyl, 2-methyl-3-methyl-1-azetidinyl or 2-phenyl-3-amino-1-azetidinyl are specifically claimed.

Description

the present invention relates to a process for the preparation of antibacterial compositions containing azetidinylquinolone esters and carboxylic acids and methods for using these compounds.

U.S. Patent 4,563,459 refers to 1-cyclopropyl-1,4-dihydro-4-oxo-quinoline carboxylic acids, wherein the fraction at position 6 is hydrogen, fluorine, chlorine, bromine or nitro and the fraction at position 7 3 4 3 4 is hydrogen, chlorine fluorine, or NR R in which R and R represent separate groups or, together with the nitrogen atom in which they are positioned, they can form a ring heterocyclic group of 5 members or 6 members.

Japanese KoKai SHO 60-89480 refers to compounds of formula

where Z is nitrogen or CH, X is halogen;

?

R and R are hydrogen, acyl or lower alkyl;

m is 1 or 2; en ê 1, 2 _N or 3. However, no

development of specific quinoline compounds.

the present invention is / concerns compounds of formula

COOR ¹ where R ¹ is hydrogen, alkyl of 1 to 6 carbon atoms 4 5 4 5 no, or NR R where R and R are independently selected from hydrogen and alkyl of 1 to 6 carbon atoms or a pharmaceutically cation acceptable,?

R is hydrogen, hydroxy, alkanoylamino of 1 to 6 carbon atoms, morpholino, halogen, hydroxy-alkyl of 1 to 6 carbon atoms, COOR where R is alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable cation , 7 o alkoxy of 1 to 6 carbon atoms, NR R where R and R are independently selected from alkyl of 1 to 6 carbon atoms, alkanoyl of 1 to 6 carbon atoms, hydrogen alkoxy of 1 to 6 atoms of carbon, aminoalkyl of 2 to 6 carbon atoms, alkylaminoalkyl in which each alkyl group is independently selected having alkyl groups having from 2 to 6 carbon atoms and dialkylaminoalkyl in; that each alkyl group is independently selected from alkyl groups having one to 6 carbon atoms

8 with the proviso that only one of the R and R can be alkoxy;

and

R is hydrogen, alkyl of 1 to 6 carbon atoms, phenyl or substituted phenyl, where the phenyl group can be substituted by one or two substituents selected from the group formed by alkyl of 1 to 6 carbon atoms, nitro, amino, halogen , (eg, fluoro, chloro, bromo or iodo), haloalkyl of 1 to 2 carbon atoms and up to 5 halogen atoms (eg, fluoro, chloro, bromo or iodo) hydroxyl or alkoxy of 1 to 6 atoms and their pharmaceutically acceptable acid addition salts.

The compounds have antibacterial activity.

the present invention also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier or diluent and a compound of formula I or a pharmaceutically acceptable salt thereof in an antibacterially effective amount. The present invention also features a method for treating an animal, including a human being, having a bacterial disease which consists of administering to the animal (e.g., mammals, birds, or fish) an antibacterially effective amount of a compound of formula I or a pharmaceutically acceptable acid addition salt thereof. The present invention can also refer to methods for the preparation of compounds of formula I.

The compounds of the invention include racemic mixtures and optical isomers. Preferred compounds of the invention are those of formula I, wherein R is hydrogenated, a pharmaceutically acceptable cation (e.g., sodium or potassium), or amino.

-1 Other preferred compounds are those of formula I, where R is hydrogen, amino, hydroxy, hydroxymethyl, acetylamino or COOR6 where R is hydrogen;

a pharmaceutically acceptable cation, or amino., Other • 3 preferred compounds are those of formula I, in which R is hydrogen or phenyl.

The most preferred compounds are those in which R is hydrogen, a pharmaceutically acceptable cation or amino; R is hydrogen, amino, or hydroxy 3 and R is hydrogen or phenyl. Specific preferred compounds are as follows:

1-cyclopropyl-6-fluoro-1,4-dihydro-7 - / “1 ¹ -azetidini17 -4-oxo-3-quinoline-carboxylic acids;

1-cyclopropi1-6 - fluoro-1,4-dihydro-7 - / “3 * -hydroxy-1 '-azetidinyl7-4-oxo-3-quino1ino-carboxylic acid

1-Cycloprop i1-6-fluoro-1,4-dihydro-7 - / “3'-amino1 '-azetidini17-4-0X03-quinoline-carboxylic acid.

1-cyclopropyl-6-fluoro-1,4-dihydro-7 - / '3'-amino-1 aceti1 -azetidini17-4 ^{1-oxo-3-quinolinecarboxylic} carboxi1ico.

The pharmaceutical compositions of the present invention preferably contain the above-specified, preferred compounds.

Other compounds of the present invention are as follows:

1-cyclopropi1-6-fluoro-1,4-dihydro-7- / 2 ¹ -phenyl-3 ¹ -amino-1 ¹ -azetidin1Z-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropyl-6-fluoro-1,4-dihydro-7 / ^{- 2, l-methyl-3} - hydroxy-1 -azetidini17-4 ^{1-oxo-3-quinoline-carboxylic} acid;

1-cyclopropi1-6-fluoro-1,4-difhydro-7 - / “2 ¹ -methyl 1-3 ¹ amino-1 ¹ -azetidini17-4-οχο-3-quinoline-carboxylic acid;

1-cyclopropi1-6-fluoro-1,4-dihydro-7- / ~ 3'-carboxyl-1 ¹ -azetidini17-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropyl1-6-fluoro-1,4-dihydro-7- / 3'-cyano-1'azetidinyl7-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropi1-6-fluoro-1,4-dihydro-7 - / “2 ¹ -ethyl-3'hydroxy-1'-azetidini17-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropi1-6-fluoro-1,4-dihydro-7- / 2 ¹ -propi1-3 ¹ amino-1'-azetidini17-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropi1-6-fluoro-1,4-dihydro-7 - / “3 ¹ -hydroxymethyl 1-1 ¹ - azetidini17-4-oxo-3-quinoline-carboxylic acid;

1-cyclopropi1-6-fluoro-1,4-dihydro-7- / 3 ¹ -amino-methyl 1-1 ¹ -azetidini17-4-oxo-3-quinolinecarboxylic acid ;.

The compounds of the present invention can be prepared by reacting the quinolone of formula

wherein R is as defined above and X is fluoro, chloro, bromo, or iodo (preferably fluoro, or chloro; more preferably fluoro) with a formula formula.

III

3 wherein R and R are as defined above, an inert solvent or a basic solvent. Examples of suitable solvents are tetrahydrofuran, pyridine, ethanol, chloroform, dimethylsulfoxide, dimethylformamide, water and mixtures thereof.

If the solvent is not a basic solvent such as, for example,

10 pyridine, it is desirable to add a base to the reaction mixture. The base serves to facilitate the completion of the reaction by reacting with the hydrogen fluoride that is produced in the reaction. The addition of DBU (which is a strong base) to the reaction mixture is preferred. A preferred solvent is a mixture of acetonitrile and 1,8-diazabicyclo (5, 4.0) -undec-7-ene (DBU). Especially preferred is the acetonitrile solvent containing 1 to 3 equivalents of DBU. Temperature and pressure are not critical. However, in general, a temperature of 30 to 100 ° C and a pressure of 0.5 to 2 atmospheres is preferred. Most preferably, ambient pressure and pressure (generally about 1 atmosphere. Although a significant amount of product can form in about 5 minutes, the reaction is usually allowed to continue overnight. The product is isolated by conventional methods.

For example, the product can be isolated by adding water to the reaction mixture, adjusting the pH to 7.0-7.4, collecting the resulting precipitate by filtration and then washing with water and drying the precipitate.

When conventional methods are used, the compounds of the present invention, where R is different from hydrogen, can be prepared by converting a compound 1 of formula I, where R is hydrogen, to the corresponding ester or starch.

Alternatively, a compound of formula II, where R is hydrogen, can be converted to the corresponding ester or starch by conventional methods and that ester or starch can then be used to prepare a compound of formula I, as previously described.

The compounds of formula II, can be prepared as described in United States Patent No. 4,563,459.

The amines or alcohols of formula III can be prepared by well-known methods. See, for example, T. Okutani et al., Chem. Pharm. Bull, 22 1490-1497 (1974); S. Chatterjee et al., Chem. Comm, 93 (1968); D. Nisato et al, J. Heterocyclic Chem. 22, 961 (1985) I. Hayakawa et al., Chem. Pharm. Bull, 32, 4907-4913 (1984); A.G. Anderson et al., J. Org. Chem. 37 3953-3955 (1972); and V.R. Gaertner J.Org.Chem. 32, 2972-2976 (1967). Thus, for example, 2-phenyl- and 2-substituted-phenyl-3-amino-azetidines can be prepared by the method of T. Okutani et al and 3-hydromethyl-1-azetidine can be prepared by the method of I. Hayakawa et al.,

The pharmaceutically acceptable acid addition salts of formula I are prepared in a conventional manner by processing a solution or suspension of the free base of formula I with approximately a chemical equivalent of a pharmaceutically acceptable acid.

Conventional concentration and recrystallization techniques are used to isolate the salts. Illustrative of suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, methanesulfonic, cinnamic fumaric, phosphonic, hydrochloric, hydrobromic, hydroidic, sulfamic and sulfonic.

-12Y

I,

The pharmaceutically acceptable cationic salts of formula I can be prepared for conventional methods from the corresponding acids, e.g., by reaction with about an equimolar amount of the base. Examples of suitable cationic salts are those of alkali metals such as sodium or potassium, alkaline earth metals such as magnesium or calcium and organic amines or ammonium such as diethanolamine or N-methylglucamine.

The compounds of formula I and their pharmaceutically acceptable acid addition salts are broad-spectrum antibacterials useful in the treatment of bacterial infections, in part in the treatment of infections of gram-positive bacterial strains.

The compounds of the present invention can be administered alone, although they are generally administered in admixture with a pharmaceutical carrier selected according to the intended route of administration and in standard pharmaceuticals. For example, they can be administered orally or in the form of tablets containing such excipients as starch or lactose, or in capsules, either alone or in mixtures with excipients, or in the form of elixirs or suspensions containing flavoring and coloring agents. In the case of animals (eg pigs, cattle, cattle, horses and poultry), they are preferably introduced into an animal feed or drinking water at a concentration of about 5 to about 5000 ppm, preferably about from 25 to about 500 ppm They can be injected parenterally, for example, intramuscularly, intravenously or subcutaneously. For parenteral administration, they are preferably used in the form of a sterile aqueous solution which may contain

-13other solutes, for example, enough salt or glucose to make the solution isotonic. In the case of animals, composed ⁰ ments can be administered intramuscularly or subcu taneous about 0.1 dosage levels of about 50 mg / kg / day., Preferably about 0.2 to about 10 mg / kg / day, given in a single daily dose or in up to 3 doses.

The invention also features pharmaceutical compositions containing an antibacterially effective amount of a compound of formula I or a pharmaceutically acceptable acid addition salt thereof together with a pharmaceutically acceptable diluent or carrier.

The compounds of the present invention can be administered to humans for the treatment of bacterial diseases either orally or parenterally and can be administered orally at dosage levels of about 0.1 to about 500 mg / kg / day, preferably from about 0.5 to about 50 mg / kg / day in a single dose or up to 3 doses. For intramuscular or intra dosage administration they are from about 0.1 to about preferably about 0.5 to about. Intramuscular administration can be dose or up to 3 doses.

levels of 200 mg / kg / day, 50 mg / kg / day. performed in one

Intravenous administration can be performed by a continuous drip system. Variations will necessarily occur depending on the weight and condition of the individual to be treated and the specific route of administration chosen, as is known to those skilled in the art.

The antibacterial activity of the compounds of the invention is revealed by testing according to the Steer replication technique, which is a standard in vitro bacterial test method described by E. Steers et al., Antibiotics and chemotherapy, 9, 307 (1959 ).

The following examples illustrate without limiting the invention. All melting points referred to in the Examples are not corrected.

Example 1

1-cyclopropyl1-6-fluoro-1,4-dihydro-7- / ~ 1 ¹ -azetidini1 / -4-oxo-3-quinoline-carboxylic acid

A mixture of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid (1,591 g, 6 mmol) acetonitrile (70 ml) azetidine (390 mg, 6 , 8 mmol) and DBU (913 mg 6 mmol)

After only 5 minutes of heating, it was observed that crystalline material was precipitating

-15talino.

After a further 5 minutes of heating the hot solution was filtered. The reaction mixture was then allowed to cool to room temperature over 1 hour.

precipitated solid material was collected by filtration, washed first with acetonitrile and then with ethyl ether and then dried to give 650 mg of the title compound, mp 298-299 ° C (dec).

NMR (DMS0-D6): 1.12-1.13 of 1.26-1.28 d, 4H, cyclopropane; 2.3-2.4, m, 2H, of Cg azetidine; 3.2-3.7, q, 1H cyclopropane; 4.19-4.24 q, 4H of azetidine C ₂ and C ₄ i 6.82-6.85, d, 1H of Cg 7.74-7.78, d, 1H of C _g ;

8.55, s, 1H, de ·

A second crop of crystals was obtained, which were washed and dried as previously described to give 210 mg of the title compound, m.p. 297-299 ° C (dec). The combined yield was 48% ·

-16Example 2

1-cyclopropi1-6-fluoro-1,4-dihydro-7- / 3'-amino-1'-azetidinyl7-4-oxo-3-quinoline-carboxylic acid and its hi salt. drochloride

A mixture of 3-amino-1-azetidine (80 mg, 0.048 mmol) of 1cyclopropyl1-6,7-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (10, 6 mg, 0.04 mol) of DBU (0.0113 ml, 12.1 mg, 0.08 mmol) in 5 ml of acetonitrile under nitrogen (79-80 ° C) for 3 hours, and was the second to then left to stand at room temperature under nitrogen overnight.

The reaction mixture was then filtered and the wet cake was washed with acetonitrile and then with ethyl ether. The cake was then dried in vacuo to give 15 mg of the title compound mp 277-278 ° C.

hydrochloride salt of the title compound was prepared by adding 130 mg (0.04 mmol) of the title compound to methanol HCl containing an equivalent amount (0.04 mmol) of HCl, stirring at room temperature for 4 hours. The crystals were collected by filtration, washed with ethyl ether and dried to give 22.3 mg of the hdirochloride salt, m.p. from above 300 ° C.

-17NMR (DMS0-D6); 1.12-1.13 d, and 1.26-1.28 d, 4H, cyclopropane, 3.8 s, 1H, cyclopropane; 4.05-4.25 m, 4H of C ₂ ^{* 1} , and C4 'azetidine; 4.46-4.52 q, 1H of C3 ¹ azetidine; 6.92-6.98 d, 1H of Cg; 7.80-7.86 d, 1H, from C ₅ ; 8.6 s, 1H of C ₂ ; 8.68-8.84 d, 2H of NH ₂ .

Example 3

1-cyclopropi1-6-fluoro-1,4-dihydro-7- / 3 ¹ -hydroxy-1 ¹ -azetidini17-4-oxo-3-quinoline-carboxylic acid

A mixture of 3-hydroxy -1-azetidine hydrochloride (120 mg, 1.1 mol) 1-cyclopropyl-6,7-difluoro-1, 4- was refluxed under nitrogen for 2.5 hours dihydro-4-oxo-quinoline-3-carboxylic (265 mg mmol), and 299 ml (2 mmol) of DBU in 10 ml of acetonitrile and then hot filtered.

wet cake was washed with nitrile acetate and dried to give 130 mg of the title compound, mp 294-295 ° C (dec).

-18Example 4

1-cyclopropyl-6-fluoro-1,4-dihydro-7 - / ”3 '-carboxyl-1 ¹ -azetidini17-4-oxo-3-quinoline-carboxylic acid and its 3'-sodium carboxylate

A mixture of 1-cyclopropyl1-6,7-di-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid was refluxed for 2 hours during 2 hours. 0.005 mmol) azetidine-3-carboxylic acid (556mg, 0.055 mmol) and DBU (0.075 mol 0.05 mol) in 5 ml of acetonitrile.

The reaction mixture was then allowed to cool to room temperature over 2 hours.

The resulting solid was suspended in 3 ml of water and the pH was adjusted to 8.5 by the addition of saturated aqueous NaHCOg solution. Ethyl ether was then added. The resulting mixture was stirred in a separatory funnel and the organic layer was separated. The aqueous layer was filtered and the filtered solution was freeze-dried overnight, obtaining 180 mg (92%) of the title compound, as disodium salt, m.p. 287-289 ° C (dec).

Example 5

1-cyclopropi1-6-fluoro-1,4-dihydro-7- / ~ 3'-acetylamino-1 ¹ -azetidinyl7-4-oxo-3-quinoline-carboxylic acid and its hydrochloride salt.

A mixture of 3-acetylamino-1-azetidine (110 mg), 0.963 mmol) 1-cyclopropyl1-6,7-difluoro-1 was refluxed under nitrogen (79-80 ° C) for one hour. , 4-dihydro-4-oxo-quinoline-3-carboxylic (212mg) 0.8mmol) and DBU (0.134ml, 137mg, 0.9mmol), in 10ml of acetonitrile, which was then left in standing at room temperature under nitrogen overnight. The reaction mixture was then filtered and the wet cake was washed with acetonitrile and then with ethyl ether. The fool was then dried in vacuo, yielding 311 mg of the title compound.

The hydrochloride salt was prepared by adding the title compound (100 mg) to methanol / HCl containing an equivalent amount of HCl and stirring at room temperature for 30 minutes.

solid material that formed was filtered, washed with acetonitrile and dried in vacuo to obtain 83.7 mg (76%) of the hydrochloride salt, mp 265-266 ° C dec.

1-cyclopropi1-6-fluoro-1,4-dihydro-7- / 2'-methyl-3 ¹ hydroxy-1 ¹ -azetidini17-4-oxo-3-quinoline-carboxylic acid

Following the method of Example 1. but using 2-methyl-3-hydroxy-1-azetidine in place of azetidine. the title compound was obtained, m.p. over 300 ° C.

Example 7

Acid 1-ciclopropi1-6-fluoro-1,4-dihydro-7 - / ^"3-hydroxy-1 meti1-1 -azetidini17-4 ^{1-oxo-3-quinolinecarboxylic} carboxi1ico

A mixture of 3-hydroxymethyl1-1-azetidine (4.4 mg, 0.05 mmol), 1-cyclopropyl1-6,7-difluoro-1, 4di was refluxed under nitrogen for 3 hours -hydro-4-oxo-quinoline-3-carboxylic (10.6 mg, 0.04iftol) and DBU (0.0113 ml, 12.1 mg 0.08 mmol) in 5 ml of acetonitrile, which was left in standing at room temperature under nitrogen overnight. The reaction mixture was then filtered and the wet cake was washed with acetonitrile and dried

-21in vacuo, yielding 9.9 mg (59%) of the title compound m.p. about 300 ° C.

Example 8

1-dclopropi1-6-fluoro-1,4-dihydro-7 - / “2'-phenyl-3 ^l amino-1'-azetidinylZ-4-oxo-3-quinoline-carboxylic acid

Reflux was carried out for 8 hours 2-pheni1-3-amino-1-azetidine dihydrochloride (9.24 mg), 0.05 mmol), 1-cyclopropi1-6,7-difluoro-1,4 -dihydro-4-oxo-quinoline-3-carboxylic (10.6 mg, 0.04 mmol) and DBU (12.1 mg, 0.08 mmol) in 15 ml of acetonitrile, which was then left to stand at room temperature overnight, under nitrogen. The mixture was then filtered, washed with acetonitrile, and dried in vacuo, yielding 6.3 mg (40%), m.p. above 300 ° C.

Example 9

The title compounds of Examples 1, 2, 3 and 5 were tested for antibacterial activity in vitro, using the Steer replication technique.

The compounds were found to be active against Staphilococcus aureus, Staphylococcus epidermis, Streptococcus pyrogenes, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pasteurella multocida, Serratia marcescens, Neisseria sicca, Enterobactere aerogenes, 3.2 micrograms per ml.

Claims (8)

1 -.- Process for the preparation of a compound of formula R ' COOR ¹ where R is hydrogen, alkyl of 1 to 6 carbon atoms, or NR ^R ^, wherein R ^ and R5 are independently selected from hydrogen and alkyl of 1 to 6 carbon atoms or 2 a pharmaceutically acceptable cation; R is hydrogen, hydroxy, alkanoylamino of 1 to 6 carbon atoms, morpholino, halogen, hydroxyalkyl of 1 to 6 carbon atoms, COOR where R is alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable cation, alkoxy of 1 to 6 atom7 8 7 8 carbon moieties, NR R, where R and R are independently selected from alkyl of 1 to 6 alkanoyl carbon atoms of 1 to 6 carbon atoms, hydrogen, alkoxy of 1 to 6 carbon atoms, aminoalkyl of 2 to 6 carbon atoms, alkylaminoalkyl, where each alkyl group is independently selected from alkyl groups having 2 to 6 carbon atoms, and dialkylaminoalkyl where each alkyl group is independently selecting from gri [ -24 alkyl points having one to six carbon atoms, with the condition 7 q q that only one of the R and R can be alkoxy; and R is hydrogen alkyl of 1 to 6 carbon atoms, phenyl or substituted phenyl in which the phenyl group can be substituted by one or two substituents selected from the group formed by alkyl of 1 to 6 carbon atoms, nitro, amino, halogen, haloalkyl of 1 to / or 2 carbon atoms and up to 5 halogen atoms, hydroxyl or alkoxy of 1 to 6 atoms and their salts, with addition of pharmaceutically acceptable acids, characterized by reacting a compound of formula in what R is as previously defined and X is fluoro, chloro, bromo or iodo, with an amine of formula R ' NH χ 'in which 2 3 R and R are as previously defined. 2. ^A process according to claim 1, characterized in that R is hydrogen, amino, hydroxy, acetylamino, hydroxymethyl or COOR in which R is hydrogen, a pharmaceutically acceptable cation or amino. 3 vindication 1, characterized pharmaceutically acceptable - Process -I for R being or amino. according to reihydrogen, a cation 4 ^â .- Process <1 vindication 1, characterized in that R is alkaline or alkaline earth metal. of an agreement with the vindication of metal vindication 1, lino or metal 5®.- Process characterized by R being alkaline earth. of an agreement with the reialca metal cation 6®.- Process vindication 1, characterized in that R is hydroxy and R is hydrogen or phenyl. according to reihydrogenio, amino or 7 .- method according to claim 6, wherein R is hydrogen, a pharmaceutically acceptable cation or amino. 8 .- process according to claim 1, wherein said compound is selected from the group consisting of acid ciclopropi1-6-1-fluoro-1,4-dihydro-7 - (/ "l ¹ 17 -azetidini -4-oxo-3-kinoyl inocarboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-7 - (/ 3 ¹ -hydroxy-1-azetidini17-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropi1-6-fluoro-1,4-dihydro-7 - / “3 ¹ -amino-1'-azetidini17-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropi1-6-fluoro-1,4-dihydro-7 - / “3'-acetyl-amino-1'-azetidini17-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropi1-6-fluoro-1,4-dihydro-7- / 2'-methyl-3-amino-1 ¹ -azetidini17-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-7 / L2 ^{1-phenyl-3-amino-1-oxo-1} -azetidinil7-4 3-quinolinocarboxi1ico; and acid addition salts of the above pharmaceutically acceptable compounds.